Doctor SHEN focuses on early-phase clinical trials and multi-center studies for new anti-cancer medications. As a prominent Principal Investigator (PI),she has overseen both international and national clinical research, contributing to the approval of 13 new drug indications. The outcomes of her research have influenced over 30 clinical practice guidelines worldwide, including those from ESMO, NCCN, CSCO, and others. She has authored more than 200 papers in Science Citation Index (SCI) journals as the first or corresponding author in esteemed publications such as Nature, BMJ, and Nature Medicine. As a key contributor, she has received several prestigious awards, including the First Prize of the Chinese Medical Science and Technology Award, the First Prize of the Chinese Anti-Cancer Association Science and Technology Award, and the First Prize of the Huaxia Medical Science and Technology Award.